Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck

International Journal of Oncology

Volumn 30, Issue 4, 2007, Pages 927-935

  Sauter, Alexander ^a   Kloft, Charlotte ^b   Gronau, Silke ^c   Bogeschdorfer, Felix ^c   Erhardt, Thomas ^d   Golze, Wolfram ^a   Schroen, Carsten ^c   Staab, Alexander ^e   Riechelmann, Herbert ^c   Hoermann, Karl ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c UNIVERSITY OF ULM   (Germany)

^d SAARLAND UNIVERSITY   (Germany)

^e BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Bivatuzumab mertansine; BIWI 1; CD44v6; Head and neck cancer; Maximum tolerated dose; Pharmacokinetics; Squamous cell carcinoma

Indexed keywords

BIVATUZUMAB MERTANSINE; CD44V6 ANTIGEN; DRUG DERIVATIVE; GLYCOPROTEIN; HERMES ANTIGEN; MAYTANSINE; MONOCLONAL ANTIBODY; PRODRUG; UNCLASSIFIED DRUG;

AGED; ARTICLE; CLINICAL TRIAL; FEMALE; HEAD AND NECK TUMOR; HUMAN; IMMUNOLOGY; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; SAFETY; SQUAMOUS CELL CARCINOMA;

AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD44; CARCINOMA, SQUAMOUS CELL; FEMALE; GLYCOPROTEINS; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MAYTANSINE; MIDDLE AGED; PRODRUGS; SAFETY;

EID: 34247890107     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.30.4.927     Document Type: Article

References (45)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer 94: 153-156, 2001.
2. Vokes EE, Weichselbaum RR, Lippman SM and Hong WK: Head and neck cancer. N Engl J Med 328: 184-194, 1993.
3. Dennington ML, Carter DR and Meyers AD: Distant metastases in head and neck epidermoid carcinoma. Laryngoscope 90: 196-201, 1980. (Pubitemid 10172323)
4. Nakanishi H, Oguri K, Takenaga K, Hosoda S and Okayama M: Differential fibrotic stromal responses of host tissue to low- and high- metastatic cloned Lewis lung carcinoma cells. Lab Invest 70: 324-332, 1994. (Pubitemid 24116526)
5. Zbaren P and Lehmann W: Frequency and sites of distant metastases in head and neck squamous cell carcinoma. An analysis of 101 cases at autopsy. Arch Otolaryngol Head Neck Surg 113: 762-764, 1987.
6. Forastiere A, Koch W, Trotti A and Sidransky D: Head and neck cancer. N Engl J Med 345: 1890-1900, 2001.
7. Al-Sarraf M: Treatment of locally advanced head and neck cancer: historical and critical review. Cancer Control 9: 387-399, 2002. (Pubitemid 35204461)
8. Brakenhoff RH, Gerretsen M, Knippels EM, van Dijk M, van Essen H, Weghuis DO, Sinke RJ, Snow GB and van Dongen GA: The human E48 antigen, highly homologous to the murine Ly-6 antigen ThB, is a GPI-anchored molecule apparently involved in keratinocyte cell-cell adhesion. J Cell Biol 129: 1677-1689, 1995.
9. Rubinfeld B, Upadhyay A, Clark SL, Fong SE, Smith V, Koeppen H, Ross S and Polakis P: Identification and immunotherapeutic targeting of antigens induced by chemotherapy. Nat Biotechnol 24: 205-209, 2006. (Pubitemid 43221705)
10. De Bree R, Roos JC, Quak JJ, den Hollander W, Snow GB and van Dongen GA: Radioimmunoscintigraphy and biodistribution of technetium-99m-labeled monoclonal antibody U36 in patients with head and neck cancer. Clin Cancer Res 1: 591-598, 1995.
11. Stroomer JW, Roos JC, Sproll M, Quak JJ, Heider KH, Wilhelm BJ, Castelijns JA, Meyer R, Kwakkelstein MO, Snow GB, Adolf GR and van Dongen GA: Safety and biodistribution of 99mTechnetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients. Clin Cancer Res 6: 3046-3055, 2000.
12. Borjesson PK, Postema EJ, Roos JC, Colnot DR, Marres HA, van Schie MH, Stehle G, De Bree R, Snow GB, Oyen WJ and van Dongen GA: Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. Clin Cancer Res 9: 3961S-3972S, 2003.
13. Heider KH, Sproll M, Susani S, Patzelt E, Beaumier P, Ostermann E, Ahorn H and Adolf GR: Characterization of a high-affinity monoclonal antibody specific for CD44v6 as candidate for immunotherapy of squamous cell carcinomas. Cancer Immunol Immunother 43: 245-253, 1996. (Pubitemid 26426258)
14. Tolcher AW, Ochoa L, Hammond LA, Patnaik A, Edwards T, Takimoto C, Smith L, De Bono J, Schwartz G, Mays T, Jonak ZL, Johnson R, De Witte M, Martino H, Audette C, Maes K, Chari RV, Lambert JM and Rowinsky EK: Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. J Clin Oncol 21: 211-222, 2003.
15. Liu C and Chari RV: The development of antibody delivery systems to target cancer with highly potent maytansinoids. Exp Opin Investig Drugs 6: 169-172, 1997. (Pubitemid 27101468)
16. Jordan A, Hadfield JA, Lawrence NJ and McGown AT: Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med Res Rev 18: 259-296, 1998. (Pubitemid 28346389)
17. Declaration of Helsinki: Recommendations guiding physicians in biomedical research involving human subjects J Am Med Assoc 277: 925-926, 1997.
18. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655, 1982.
19. FDA: Guidance for Industry. Bioanalytical Method Validation. www.fda.gov/cder/guidance/4252fnl.pdf, 2001.
20. Gabrielsson J and Weiner D: Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications. Swedish Pharmaceutical Press, Stockholm, 2000.
21. Wu AM and Senter PD: Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 23: 1137-1146, 2005.
22. FDA: NDA 21-174/S-002, 2001.
23. Heider KH, Mulder JW, Ostermann E, Susani S, Patzelt E, Pals ST and Adolf GR: Splice variants of the cell surface glycoprotein CD44 associated with metastatic tumour cells are expressed in normal tissues of humans and cynomolgus monkeys. Eur J Cancer 31A: 2385-2391, 1995. (Pubitemid 26050584)
24. Eagan RT, Ingle JN, Rubin J, Frytak S and Moertel CG: Early clinical study of an intermittent schedule for maytansine (NSC-153858): brief communication. J Natl Cancer Inst 60: 93-96, 1978. (Pubitemid 8287174)
25. Eagan RT, Creagan ET, Ingle JN, Frytak S and Rubin J: Phase II evaluation of maytansine in patients with metastatic lung cancer. Cancer Treat Rep 62: 1577-1579, 1978. (Pubitemid 9082670)
26. Chahinian AP, Nogeire C, Ohnuma T, Greenberg ML, Sivak M, Jaffrey IS and Holland JF: Phase I study of weekly maytansine given by iv bolus or 24-h infusion. Cancer Treat Rep 63: 1953-1960, 1979.
27. Blum RH and Kahlert T: Maytansine: a phase I study of an ansa macrolide with antitumor activity. Cancer Treat Rep 62: 435-438, 1978.
28. Xie H, Audette C, Hoffee M, Lambert JM and Blattler WA: Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice. J Pharmacol Exp Ther 308: 1073-1082, 2004. (Pubitemid 38263984)
29. Colnot DR, Quak JJ, Roos JC, van Lingen A, Wilhelm AJ, van Kamp GJ, Huijgens PC, Snow GB and van Dongen GA: Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck. J Nucl Med 41: 1999-2010, 2000.
30. Koppe M, Schaijk F, Roos J, Leeuwen P, Heider KH, Kuthan H and Bleichrodt R: Safety, pharmacokinetics, immunogenicity, and biodistribution of (186)Re-labeled humanized monoclonal antibody BIWA 4 (Bivatuzumab) in patients with early-stage breast cancer. Cancer Biother Radiopharm 19: 720-729, 2004. (Pubitemid 40279580)
31. Lobo ED, Hansen RJ and Balthasar JP: Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93: 2645-2668, 2004.
32. Bauer RJ, Dedrick RL, White ML, Murray MJ and Garovoy MR: Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J Pharmacokinet Biopharm 27: 397-420, 1999.
33. Kovarik J, Wolf P, Cisterne JM, Mourad G, Lebranchu Y, Lang P, Bourbigot B, Cantarovich D, Girault D, Gerbeau C, Schmidt AG and Soulillou JP: Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts. Transplantation 64: 1701-1705, 1997.
34. Kuester K and Kloft C: Pharmacokinetics of monoclonal antibodies. In: Pharmacokinetics and Pharmacodynamics of Biotech Drugs: Principles and Case Studies in Drug Development. Meibohm B (ed). Wiley-VCH, Weinheim, pp45-91, 2006.
35. Chow FS, Benincosa LJ, Sheth SB, Wilson D, Davis CB, Minthorn EA and Jusko WJ: Pharmacokinetic and pharmacodynamic modeling of humanized anti-factor IX antibody (SB 249417) in humans. Clin Pharmacol Ther 71: 235-245, 2002. (Pubitemid 34311452)
36. Dowell JA, Korth-Bradley J, Liu H, King SP and Berger MS: Pharmacokinetics of gemtuzumab ozogamicin, an antibodytargeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J Clin Pharmacol 41: 1206-1214, 2001. (Pubitemid 32983219)
37. Everitt DE, Davis CB, Thompson K, Di Cicco R, Ilson B, Demuth SG, Herzyk DJ and Jorkasky DK: The pharmacokinetics, antigenicity, and fusion-inhibition activity of RSHZ19, a humanized monoclonal antibody to respiratory syncytial virus, in healthy volunteers. J Infect Dis 174: 463-469, 1996. (Pubitemid 26299677)
38. Loh A, Sgouros G, O'Donoghue JA, Deland D, Puri D, Capitelli P, Humm JL, Larson SM, Old LJ and Divgi CR: Pharmacokinetic model of iodine-131-G250 antibody in renal cell carcinoma patients. J Nucl Med 39: 484-489, 1998. (Pubitemid 28136848)
39. Tokuda Y, Watanabe T, Omuro Y, Ando M, Katsumata N, Okumura A, Ohta M, Fujii H, Sasaki Y, Niwa T and Tajima T: Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. Br J Cancer 81: 1419-1425, 1999.
40. Kloft C, Graefe EU, Tanswell P, Scott AM, Hofheinz R, Amelsberg A and Karlsson MO: Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patients. Invest New Drugs 22: 39-52, 2004. (Pubitemid 38196981)
41. Waldmann TA and Strober W: Metabolism of immunoglobulins. Prog Allergy 13: 1-110, 1969.
42. Morell A, Terry WD and Waldmann TA: Metabolic properties of IgG subclasses in man. J Clin Invest 49: 673-680, 1970.
43. Ghetie V, Popov S, Borvak J, Radu C, Matesoi D, Medesan C, Ober RJ and Ward ES: Increasing the serum persistence of an IgG fragment by random mutagenesis. Nat Biotechnol 15: 637-640, 1997. (Pubitemid 27291163)
44. Kovarik JM, Nashan B, Neuhaus P, Clavien PA, Gerbeau C, Hall ML and Korn A: A population pharmacokinetic screen to identify demographic-clinical covariates of basiliximab in liver transplantation. Clin Pharmacol Ther 69: 201-209, 2001. (Pubitemid 32382502)
45. Wiseman LR and Faulds D: Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients. Drugs 58: 1029-1042, 1999.